Wells Fargo’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-21,782
| Closed | -$48.1K | – | 7732 |
|
|
2023
Q2 | $48.1K | Sell |
21,782
-252
| -1% | -$523 | ﹤0.01% | 5445 |
|
|
2023
Q1 | $56K | Sell |
22,034
-2,021
| -8% | -$3.99K | ﹤0.01% | 5108 |
|
|
2022
Q4 | $45K | Buy |
24,055
+14,176
| +143% | +$35.3K | ﹤0.01% | 4907 |
|
|
2022
Q3 | $26K | Sell |
9,879
-26
| -0.3% | -$65 | ﹤0.01% | 5281 |
|
|
2022
Q2 | $19K | Sell |
9,905
-85,699
| -90% | -$187K | ﹤0.01% | 5492 |
|
|
2022
Q1 | $284K | Sell |
95,604
-136,598
| -59% | -$514K | ﹤0.01% | 4778 |
|
|
2021
Q4 | $1.04M | Sell |
232,202
-5,786
| -2% | -$27.4K | ﹤0.01% | 4067 |
|
|
2021
Q3 | $1.16M | Sell |
237,988
-35,336
| -13% | -$195K | ﹤0.01% | 4119 |
|
|
2021
Q2 | $1.86M | Buy |
273,324
+42,155
| +18% | +$341K | ﹤0.01% | 3748 |
|
|
2021
Q1 | $1.63M | Buy |
231,169
+98,967
| +75% | +$713K | ﹤0.01% | 3872 |
|
|
2020
Q4 | $828K | Buy |
132,202
+21,264
| +19% | +$125K | ﹤0.01% | 4169 |
|
|
2020
Q3 | $600K | Sell |
110,938
-2,241
| -2% | -$11.1K | ﹤0.01% | 4218 |
|
|
2020
Q2 | $591K | Buy |
113,179
+68,862
| +155% | +$306K | ﹤0.01% | 4200 |
|
|
2020
Q1 | $140K | Buy |
44,317
+28,246
| +176% | +$104K | ﹤0.01% | 4891 |
|
|
2019
Q4 | $65K | Buy |
16,071
+85
| +0.5% | +$295 | ﹤0.01% | 5435 |
|
|
2019
Q3 | $69K | Buy |
15,986
+1,473
| +10% | +$5.89K | ﹤0.01% | 5460 |
|
|
2019
Q2 | $59K | Sell |
14,513
-66,162
| -82% | -$315K | ﹤0.01% | 5492 |
|
|
2019
Q1 | $432K | Buy |
80,675
+5,369
| +7% | +$34.7K | ﹤0.01% | 4425 |
|
|
2018
Q4 | $386K | Buy |
75,306
+31,663
| +73% | +$240K | ﹤0.01% | 4494 |
|
|
2018
Q3 | $422K | Buy |
43,643
+5,056
| +13% | +$51K | ﹤0.01% | 4553 |
|
|
2018
Q2 | $393K | Buy |
38,587
+11,089
| +40% | +$125K | ﹤0.01% | 4636 |
|
|
2018
Q1 | $357K | Buy |
27,498
+8,140
| +42% | +$121K | ﹤0.01% | 4633 |
|
|
2017
Q4 | $346K | Buy |
19,358
+2,533
| +15% | +$52.9K | ﹤0.01% | 4657 |
|
|
2017
Q3 | $422K | Sell |
16,825
-250
| -1% | -$5.82K | ﹤0.01% | 4435 |
|
|
2017
Q2 | $411K | Buy |
17,075
+1,509
| +10% | +$33.4K | ﹤0.01% | 4344 |
|
|
2017
Q1 | $300K | Buy |
15,566
+1,400
| +10% | +$22.1K | ﹤0.01% | 4566 |
|
|
2016
Q4 | $218K | Buy |
14,166
+6,161
| +77% | +$80K | ﹤0.01% | 4720 |
|
|
2016
Q3 | $104K | Buy |
8,005
+5,305
| +196% | +$70.3K | ﹤0.01% | 4896 |
|
|
2016
Q2 | $38K | Sell |
2,700
-132
| -5% | -$1.94K | ﹤0.01% | 5308 |
|
|
2016
Q1 | $43K | Hold |
2,832
| – | – | ﹤0.01% | 5274 |
|
|
2015
Q4 | $54K | Sell |
2,832
-14
| -0.5% | -$267 | ﹤0.01% | 5252 |
|
|
2015
Q3 | $54K | Buy |
2,846
+2,153
| +311% | +$53.7K | ﹤0.01% | 5240 |
|
|
2015
Q2 | $18K | Sell |
693
-4,217
| -86% | -$120K | ﹤0.01% | 5640 |
|
|
2015
Q1 | $154K | Sell |
4,910
-1,935
| -28% | -$55.6K | ﹤0.01% | 4551 |
|
|
2014
Q4 | $264K | Buy |
6,845
+6,762
| +8,147% | +$161K | ﹤0.01% | 4290 |
|
|
2014
Q3 | $2K | Hold |
83
| – | – | ﹤0.01% | 6011 |
|
|
2014
Q2 | $2K | Hold |
83
| – | – | ﹤0.01% | 5960 |
|
|
2014
Q1 | $3K | Hold |
83
| – | – | ﹤0.01% | 5646 |
|
|
2013
Q4 | $3K | Hold |
83
| – | – | ﹤0.01% | 5496 |
|
|
2013
Q3 | $3K | Hold |
83
| – | – | ﹤0.01% | 5399 |
|
|
2013
Q2 | $3K | Buy |
+83
| New | +$3.56K | ﹤0.01% | 5332 |
|
Wells Fargo's PRTK Position: Q3 2023 in Review
Wells Fargo sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 21,782 shares — an estimated $48.1K sold.
Wells Fargo first reported a position in PRTK in Q2 2013 and held it in 41 quarters. The position peaked at $1.86M in Q2 2021. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Wells Fargo reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Wells Fargo sold 21,782 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $48.1K.
- Wells Fargo first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 41 quarters.
- Wells Fargo's Paratek Pharmaceuticals, Inc. position peaked at $1.86M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Wells Fargo's 13F filing for Q3 2023, filed 13 Nov 2023.